Estimating Rebates and Other Discounts Received by Medicare Part D

Authors:

Abstract
Medicare Part D spending represents nearly one-third of retail prescription drug spending in the US.1 Researchers have examined a variety of strategies to limit spending, including international reference pricing,2 direct price negotiation,3-5 and substitution of less expensive but therapeutically equivalent products.6-10 Studies modeling the effects of such policy changes on Medicare Part D spending have a common limitation: none can fully account for confidential rebates or other discounts that drug manufacturers and pharmacies provide to Medicare Part D plans.

This publication has 18 references indexed in Scilit: